NASDAQ:APLS Apellis Pharmaceuticals (APLS) Stock Price, News & Analysis $41.03 0.00 (0.00%) As of 05/14/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Apellis Pharmaceuticals Stock (NASDAQ:APLS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get APLS alerts:Sign Up Key Stats Today's Range$41.03▼$41.0750-Day Range$16.97▼$41.1252-Week Range$16.10▼$41.14Volume68.61 million shsAverage Volume7.54 million shsMarket Capitalization$5.25 billionP/E Ratio40.23Dividend YieldN/APrice Target$35.72Consensus RatingHold Company Overview Apellis Pharmaceuticals, Inc., traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life. The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders. In addition to its ophthalmology programs, Apellis is advancing clinical candidates in hematology, including indications such as paroxysmal nocturnal hemoglobinuria (PNH), and in rare kidney diseases like C3 glomerulopathy. Its diversified pipeline reflects a strategy to address high-unmet-need populations across multiple therapeutic areas. Founded in 2003 and headquartered in Waltham, Massachusetts, Apellis operates with a global footprint, conducting clinical trials and engaging regulatory authorities in key markets including the United States, Europe and Asia. The company collaborates with research institutions and industry partners to enhance its discovery engine and advance its development candidates from preclinical studies through late-stage trials. Apellis is led by President and Chief Executive Officer Cedric Francois, who brings extensive experience in biotechnology and drug development. Under his leadership, the company continues to expand its scientific capabilities and pursue strategic initiatives aimed at delivering transformative therapies to patients worldwide.AI Generated. May Contain Errors. Read More Apellis Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreAPLS MarketRank™: Apellis Pharmaceuticals scored higher than 30% of companies evaluated by MarketBeat, and ranked 741st out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingApellis Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.09, and is based on no strong buy ratings, 3 buy ratings, 18 hold ratings, and 1 sell rating.Downside RiskApellis Pharmaceuticals has a consensus price target of $35.72, representing about 12.9% downside from its current price of $41.03.Amount of Analyst CoverageApellis Pharmaceuticals has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Apellis Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Apellis Pharmaceuticals are expected to grow in the coming year, from ($1.14) to ($0.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apellis Pharmaceuticals is 40.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.39.Price to Earnings Ratio vs. SectorThe P/E ratio of Apellis Pharmaceuticals is 40.23, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.79.Price to Book Value per Share RatioApellis Pharmaceuticals has a P/B Ratio of 12.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Apellis Pharmaceuticals' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.01% of the float of Apellis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverApellis Pharmaceuticals has a short interest ratio ("days to cover") of 3.06, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Apellis Pharmaceuticals has recently decreased by 24.48%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldApellis Pharmaceuticals does not currently pay a dividend.Dividend GrowthApellis Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 6 news articles for Apellis Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 3 people have searched for APLS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Apellis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Apellis Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders6.50% of the stock of Apellis Pharmaceuticals is held by insiders.Percentage Held by Institutions96.29% of the stock of Apellis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Apellis Pharmaceuticals' insider trading history. Receive APLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APLS Stock News HeadlinesPromising Mid Cap Stocks To Keep An Eye On - May 15thMay 17 at 4:55 AM | americanbankingnews.comTop Pharmaceutical Stocks To Add to Your Watchlist - May 14thMay 16 at 4:49 AM | americanbankingnews.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.May 19 at 1:00 AM | Banyan Hill Publishing (Ad)Best Medical Stocks To Keep An Eye On - May 14thMay 16 at 4:49 AM | americanbankingnews.comApellis Pharmaceuticals (NASDAQ:APLS) Upgraded at Wall Street ZenMay 16 at 1:18 AM | americanbankingnews.comApellis Updates Executive Separation Plan Amid Biogen MergerMay 5, 2026 | theglobeandmail.com$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—CZNL, HLX, APLS, and SLNOMay 5, 2026 | globenewswire.comApellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll onApril 20, 2026 | msn.comSee More Headlines APLS Stock Analysis - Frequently Asked Questions How have APLS shares performed this year? Apellis Pharmaceuticals' stock was trading at $25.12 at the beginning of the year. Since then, APLS stock has increased by 63.3% and is now trading at $41.03. How were Apellis Pharmaceuticals' earnings last quarter? Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) posted its earnings results on Thursday, May, 7th. The company reported $0.15 EPS for the quarter, topping the consensus estimate of ($0.29) by $0.44. The company earned $268.30 million during the quarter, compared to analyst estimates of $208.91 million. Apellis Pharmaceuticals had a trailing twelve-month return on equity of 39.71% and a net margin of 12.06%. Does Apellis Pharmaceuticals have any subsidiaries? Apellis Pharmaceuticals subsidiaries include these companies: Potentia Pharmaceuticals, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., and others. When did Apellis Pharmaceuticals IPO? Apellis Pharmaceuticals (APLS) raised $150 million in an IPO on Thursday, November 9th 2017. The company issued 10,714,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO. Who are Apellis Pharmaceuticals' major shareholders? Top institutional shareholders of Apellis Pharmaceuticals include Dimensional Fund Advisors LP (1.05%), Healthcare of Ontario Pension Plan Trust Fund (0.94%), Bank of America Corp DE (0.93%) and Kryger Capital LLC (0.86%). Insiders that own company stock include Pascal Deschatelets, Alec Machiels, Cedric Francois, Mark Jeffrey Delong, Timothy Eugene Sullivan, Adam J Townsend, David O Watson, Caroline Baumal, Nur Nicholson, Lukas Scheibler, Jeffrey Eisele, James George Chopas, Karen Lewis and A Sinclair Dunlop. View institutional ownership trends. How do I buy shares of Apellis Pharmaceuticals? Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Apellis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Apellis Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings5/07/2026Today5/19/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 APLS's financial health is in the Green zone, according to TradeSmith. APLS has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APLS CIK1492422 Webwww.apellis.com Phone(617) 977-5700FaxN/AEmployees770Year Founded2009Price Target and Rating Average Price Target for Apellis Pharmaceuticals$35.72 High Price Target$52.00 Low Price Target$18.00 Potential Upside/Downside-12.9%Consensus RatingHold Rating Score (0-4)2.09 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)$1.02 Trailing P/E Ratio40.23 Forward P/E RatioN/A P/E GrowthN/ANet Income$22.39 million Net Margins12.06% Pretax Margin12.23% Return on Equity39.71% Return on Assets13.20% Debt Debt-to-Equity Ratio0.87 Current Ratio3.63 Quick Ratio3.16 Sales & Book Value Annual Sales$1.11 billion Price / Sales4.75 Cash Flow$0.21 per share Price / Cash Flow196.33 Book Value$3.24 per share Price / Book12.66Miscellaneous Outstanding Shares128,021,000Free Float119,700,000Market Cap$5.25 billion OptionableOptionable Beta-0.24 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:APLS) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
